

Financial news for ACT dated on 2020-03-26: AdvisorShares Cannabis And Vice ETF Manager To Host Webinar At 4pm ET

Financial news for ACT dated on 2019-04-21: A Second Marijuana ETF Ignites

Financial news for ACT dated on 2019-04-17: YOLO? US Investors Are Getting Another Cannabis ETF

Financial news for ACT dated on 2019-03-27: Vice And Cannabis Are In With This ETF

Financial news for ACT dated on 2019-01-30: AdvisorShares Eyes Marijuana ETF Listing

Financial news for ACT dated on 2017-12-14: What Were Once Vices Are Now Dividends: A Sinful New ETF

Financial news for ACT dated on 2016-11-03: Hearing Dept. of Justice is Probing Generic Cos., Mylan, Teva, Actavis, Impax, Endo's Par, Covis, Lannett, Others Received Subpoenas

Financial news for ACT dated on 2015-08-14: 13F from Barry Rosenstein's JANA Partners Shows Dissolved Sole Share Stake in Actavis, Takes Sole Share Stake of 1.6M Shares in Allergan

Financial news for ACT dated on 2015-08-03: 5 Biotechs With Catalysts Coming This Week

Financial news for ACT dated on 2015-07-14: Delivering Alpha: What's Coming?

Financial news for ACT dated on 2015-06-15: Actavis plc Becomes Allergan plc

Financial news for ACT dated on 2015-06-08: Microsoft, Apple & Actavis Among Hedgies', Mutual Fund's Favorite Stocks

Financial news for ACT dated on 2015-06-04: Actavis Reports FDA Approval of NATRELLE INSPIRA Round Gel-Filled Textured Breast Implants

Financial news for ACT dated on 2015-06-04: BofA On Actavis: 'ACT Now And Don't Wait Much Longer'

Financial news for ACT dated on 2015-06-03: Analyst Knocks High-Profile Biotech Merger Battle; Opportunities Elsewhere

Financial news for ACT dated on 2015-06-03: Raymond James Initiates Actavis With Outperform

Financial news for ACT dated on 2015-06-03: Benzinga's Top Initiations

Financial news for ACT dated on 2015-06-03: Raymond James Initiates Coverage on Actavis at Outperform, Announces \$344.00 PT

Financial news for ACT dated on 2015-06-02: Actavis, Perrigo Recieve FDA Approval Of Guaifenesin/Pseudoephedrine, The Store Brand Equivalent To Mucinex D Tablets

Financial news for ACT dated on 2015-05-28: Valeant, Actavis Neck And Neck With Bowel Disorder Drugs

Financial news for ACT dated on 2015-05-28: Cannacord Boosts Valeant Pharma Price Target On IBS-D Approval

Financial news for ACT dated on 2015-05-27: Actavis Release Confirms FDA Approval for VIBERZI for Treatment of IBS with Diarrhea in Adults

Financial news for ACT dated on 2015-05-27: FDA Approves Salix Pharma's Xifaxan, Patheon's Viberzi for IBS

Financial news for ACT dated on 2015-05-22: Actavis Says Court Upheld Preliminary Injunction On NAMENDA

Financial news for ACT dated on 2015-05-22: Injunction on Actavis Holds Up in NY Appeals Court

Financial news for ACT dated on 2015-05-22: Valeant CEO: Healthcare Sector A 'Bit Of A Bubble'

Financial news for ACT dated on 2015-05-18: Viking Global Liked AIG, Google, Actavis, Illumina And Cheniere Energy Last Quarter

Financial news for ACT dated on 2015-05-18: Synergy Rallies 18% Following News of Paulson & Co. Stake

Financial news for ACT dated on 2015-05-18: Actavis Reports Launch of NAMZARIC for Treatment of Moderate-to-Severe Alzheimer's

Financial news for ACT dated on 2015-05-17: John Paulson Continues To Bet On Health Care And TV

Financial news for ACT dated on 2015-05-16: Bill Ackman's Latest Moves In Health Care & Some Other Positions From Q1

Financial news for ACT dated on 2015-05-15: Only Notable Change Seen in Ackman's Pershing Square 13F Was New Stake in Actavis, Valeant

Financial news for ACT dated on 2015-05-15: Tiger Management Likes Chinese Tech Stocks, Cheniere Energy And Actavis

Financial news for ACT dated on 2015-05-15: Leon Cooperman's Omega Advisors Sells Apple, Gilead; Buys Humana, GM And IBM

Financial news for ACT dated on 2015-05-13: How Is The Market Valuing Actavis?

Financial news for ACT dated on 2015-05-12: Canaccord On Actavis: 'Consensus Isn't Always Wrong'

Financial news for ACT dated on 2015-05-12: Leerink Is Changing Targets At These 7 Biotechs

Financial news for ACT dated on 2015-05-12: Cantor Slaps 'Buy' Rating On Paratek Pharmaceuticals

Financial news for ACT dated on 2015-05-11: Morning Market Gainers

Financial news for ACT dated on 2015-05-11: On Conf. Call Actavis Says Another Large "US deal won't give us anything"

Financial news for ACT dated on 2015-05-11: Benzinga's Top #PreMarket Gainers

Financial news for ACT dated on 2015-05-11: US Stock Futures Edge Higher

Financial news for ACT dated on 2015-05-11: Actavis Beats Q1 Expectations, Shares Jump

Financial news for ACT dated on 2015-05-11: Actavis Expects FY EPS \$17 to \$18.50, Est \$17.70

Financial news for ACT dated on 2015-05-11: Actavis Q1 EPS \$4.30 vs \$3.94 est, Revenue \$4.23B vs \$4.03B est

Financial news for ACT dated on 2015-05-11: Earnings Scheduled For May 11, 2015

Financial news for ACT dated on 2015-05-08: Barclays Hopes Pulmicort Is 'Back For Good' At Actavis

Financial news for ACT dated on 2015-05-08: Mizuho Gives Actavis Buy Rating Following AGN Acquisition Close

Financial news for ACT dated on 2015-05-07: Mizuho Securities Initiates Coverage on Actavis at Buy, Announces \$358.00 PT

Financial news for ACT dated on 2015-05-07: Actavis Earlier After-Hours Release Announced Co. to Immediately Re-Launch Generic Version of AstraZeneca's Pulmicort RESPULES

Financial news for ACT dated on 2015-05-07: AstraZeneca Has Lost Appeal Related to Pulmicort Respules Being Invalid; BZ NOTE: Actavis Winner Here

Financial news for ACT dated on 2015-05-04: Cooperman Likes Actavis

Financial news for ACT dated on 2015-05-04: RBC Capital's Top 20 U.S. Stock Picks

Financial news for ACT dated on 2015-05-04: Ira Sohn Conference Live Blog: Movers, Shakers, Hedge Comments

Financial news for ACT dated on 2015-05-01: Viking Global's Shareholder Letter Talks New Positions In Google, Cheniere, Biggest Winners & Losers

Financial news for ACT dated on 2015-04-28: Actavis, Medicines360 Report Publication of ACCESS IUS Efficacy, Safety Study of LILETTA

Financial news for ACT dated on 2015-04-24: Actavis Reports Topline Phase 3 Clinical Trial Results for Single-Dose DALVANCE (dalbavancin) in the Treatment of ABSSSI

Financial news for ACT dated on 2015-04-20: Actavis Announces COO Charles Mayr to Retire, Alex Kelly to Replace

Financial news for ACT dated on 2015-04-20: Actavis Reports FDA Approval of Expanded Label for BOTOX

Financial news for ACT dated on 2015-04-17: UPDATE: Actavis Trading Down From \$296.56 To \$292.73 After Amerigen Pharma. Announces Tentative FDA Approval Of Generic Bystolic

Financial news for ACT dated on 2015-04-17: Amerigen Reports Tentative Approval Of Generic Bystolic By FDA; Actavis Seeing A Dip In Price Off Of This Approval

Financial news for ACT dated on 2015-04-13: Actavis, Medicines360 Report U.S. Availability of LILETTA (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy Up To Three Years

Financial news for ACT dated on 2015-04-13: Actavis, Medicines360 Report US Availability of LILETTA

Financial news for ACT dated on 2015-04-10: Morgan Stanley: We Still Like Actavis Despite Weaknesses

Financial news for ACT dated on 2015-04-09: And The Winner From The Mylan-Perrigo Merger Is... Teva?

Financial news for ACT dated on 2015-04-08: Rhythm Begins Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis

Financial news for ACT dated on 2015-04-03: Actavis Confirms it Filed NDA To Market Letairis Generic

Financial news for ACT dated on 2015-04-01: Bank Of America's 10 Most Explosive Stock Picks

Financial news for ACT dated on 2015-03-31: Benzinga's M&A Chatter for Tuesday March 31, 2015

Financial news for ACT dated on 2015-03-31: Hearing The Deal Says Momenta Takeover Target for Actavis, Teva

Financial news for ACT dated on 2015-03-30: Amneal to Acquire Generic Business of Actavis Australia

Financial news for ACT dated on 2015-03-17: Actavis Announces Michael Gallagher, Peter McDonnell Will Join Co. Board

Financial news for ACT dated on 2015-03-17: Actavis Completes Allergan Acquisition For Approx \$70.5B In Cash, Equity Deal

Financial news for ACT dated on 2015-03-17: Goldman Sachs Reinstates Buy on Actavis, Announces \$365.00 PT

Financial news for ACT dated on 2015-03-16: Actavis Recieves FDA Approval For VIIBRYD

Financial news for ACT dated on 2015-03-16: Actavis Announces European Commission Has Cleared Co.'s Pending Purchase of Allergan

Financial news for ACT dated on 2015-03-13: Actavis Recieves FDA Approval FOR SAPHRIS For Acute Treatment Of Bipolar Disorder In 10-17 Age Patients

Financial news for ACT dated on 2015-03-12: Actavis Release Confirms Appeals Court Has Granted Injunction Related to Pending Appeal Related to Generic Pulmicort Repsules

Financial news for ACT dated on 2015-03-12: Actavis Announces Closing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan

Financial news for ACT dated on 2015-03-11: Citigroup Says Actavis Is Now Worth \$360 Per Share (And It's A Buy)

Financial news for ACT dated on 2015-03-11: JP Morgan Reinstates Overweight on Actavis, Announces \$375.00 PT

Financial news for ACT dated on 2015-03-09: Actavis Launches Generic Version Of Temovate

Financial news for ACT dated on 2015-03-09: Vivus Says on March 4, Co Filed Lawsuit In U.S. District Court for District of NJ vs Actavis, Based on Actavis' Submission Of aNDA Which Infringes Intellectual Property Rights Relating to Qsymia

Financial news for ACT dated on 2015-03-06: Actavis' Avycaz Delivers A One-Two Punch To Superbugs

Financial news for ACT dated on 2015-03-06: Benzinga's Top Initiations

Financial news for ACT dated on 2015-03-06: Edward Jones Initiates Actavis At Buy

Financial news for ACT dated on 2015-03-06: Edward Jones Initiates Coverage on Actavis at Buy

Financial news for ACT dated on 2015-03-04: Actavis Announces Confirmation of District Court Ruling in Atelvia Patent Case: Says Court Found Protecting Patents 'Invalid'

Financial news for ACT dated on 2015-03-04: US Judge Rules in Favor of Teva Pharmaceutical Industries vs Actavis in Patent Litigation Involving Atelvia Osteoporosis Drug -Reuters

Financial news for ACT dated on 2015-03-02: Books on Actavis Jumbo Acquisition Bond at \$65B+, According to Source -Reuters

Financial news for ACT dated on 2015-03-02: Hearing Vague Unconfirmed Market Chatter of Renewed Potential Interest from Pfizer in Actavis

Financial news for ACT dated on 2015-03-02: Option Alert: Actavis Mar 6 \$302.5 Call; 2689 Contract Trade Above Ask @\$1.26; Now \$295.55

Financial news for ACT dated on 2015-03-02: Actavis Receives Approval From European Commission For XYDALBA

Financial news for ACT dated on 2015-03-02: Actavis Announces Public Offering Pending Allergan Acquisition

Financial news for ACT dated on 2015-02-27: Actavis and Medicines360 Announce FDA Approval of LILETTA

Financial news for ACT dated on 2015-02-25: Actavis Receives U.S. FDA Approval for AVYCAZ

Financial news for ACT dated on 2015-02-25: FDA Approves Avycaz

Financial news for ACT dated on 2015-02-25: Actavis Reports Pricing of Public Offerings of Ordinary Shares, Mandatory Convertibles: 13.2M Shares Priced at \$288/Share

Financial news for ACT dated on 2015-02-25: Actavis Prices 13.194M Share Offering at \$288/Share -Filing

Financial news for ACT dated on 2015-02-25: Actavis Shares Higher in Premarket as Co Confirms ANDA Filing to FDA for Generic Version of Salix' Uceris

Financial news for ACT dated on 2015-02-24: Actavis To Begin 3-day Roadshow for Allergan Acquisition Bond On Wednesday, According to Source -Reuters

Financial news for ACT dated on 2015-02-20: UPDATE: Actavis Receives Final Approval for Generic Version of Subutex

Financial news for ACT dated on 2015-02-20: Actavis Receives Final Approval for Generic Version of Subutex

Financial news for ACT dated on 2015-02-19: ValueWalk On What Might Be Pershing Square's 'Big Secret Short'

Financial news for ACT dated on 2015-02-19: Actavis, NRG Energy, Wal-Mart, Zoetis, Best Buy, Mentioned by ValueWalk as Potential Ackman Shorts

Financial news for ACT dated on 2015-02-19: Actavis' Growth 'Underappreciated,' Sterne Agee Says

Financial news for ACT dated on 2015-02-19: Actavis Announces Proposed Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan

Financial news for ACT dated on 2015-02-19: Filing from Actavis Shows Registration

for Automatic Mixed Securities Shelf Offering

Financial news for ACT dated on 2015-02-18: A Look At Dan Loeb's Diversified 13F

Financial news for ACT dated on 2015-02-18: Stephen Mandel's Lone Pine Capital Loves Tech, Consumer Stocks

Financial news for ACT dated on 2015-02-18: Paulson & Company's Q4 Moves: Healthcare And Beyond

Financial news for ACT dated on 2015-02-18: UPDATE: Actavis Tops Q4 Views

Financial news for ACT dated on 2015-02-18: US Stock Futures Mostly Flat; FOMC Minutes In Focus

Financial news for ACT dated on 2015-02-18: Actavis to Adopt 'Allergan' Corporate Name

Financial news for ACT dated on 2015-02-18: Actavis Q4 EPS \$3.91 vs \$3.91, Sales \$4.06B vs 3.84B

Financial news for ACT dated on 2015-02-18: Earnings Scheduled For February 18, 2015

Financial news for ACT dated on 2015-02-18: Earning & Economic Calendar for Wednesday February 18, 2015

Financial news for ACT dated on 2015-02-17: 13F from Lone Pine Capital Shows New Stakes in Visa, DaVita, Liquidated Positions in Comcast, Gap, Actavis; Reduced Stakes in Microsoft, Wynn, Michael Kors, Valeant, Increased Stake in Priceline, Mastercard, Facebook

Financial news for ACT dated on 2015-02-17: Actavis Reports Confirmation of Temporary Injunction from Appeals Court Related to Generic Pulmicort RESPULES

Financial news for ACT dated on 2015-02-13: Actavis Launches Generic Version Of AstraZeneca's Pulmicort RESPULES

Financial news for ACT dated on 2015-02-13: Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, Trims McDonald's In Q4

Financial news for ACT dated on 2015-02-13: Sterne Agee Dives Deep Into 3 Biotechs

Financial news for ACT dated on 2015-02-13: Actavis To Divest Pharmatect To TPG, No Terms Disclosed

Financial news for ACT dated on 2015-02-09: Actavis Announces Divestiture of Doryx to Mayne Pharma for \$50M

Financial news for ACT dated on 2015-02-06: After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?

Financial news for ACT dated on 2015-02-06: Should Ligand Pharmaceuticals Worry Investors?

Financial news for ACT dated on 2015-02-05: US Stock Futures Surge Ahead Of Jobless Claims Data

Financial news for ACT dated on 2015-02-05: AstraZeneca to Acquire Rights to Actavis' Branded Respiratory Business in U.S., Canada for Initial Consideration of \$600M

Financial news for ACT dated on 2015-02-04: Actavis Announces FDA Accepted sNDA for Expansion of TEFLARO Labeling

Financial news for ACT dated on 2015-02-02: Gilead Could Miss Earnings (Hint: Watch Drug Sales)

Financial news for ACT dated on 2015-02-02: Actavis CEO: You Have To Be Committed To R&D And Innovation To Be Successful Long-Term In Our Industry

Financial news for ACT dated on 2015-01-27: White House Budget To Support Biotech Rally

Financial news for ACT dated on 2015-01-27: Citigroup Ponders How Results From Namenda Survey Might Affect Actavis

Financial news for ACT dated on 2015-01-26: Benzinga's M&A Chatter for Monday January 26, 2015

Financial news for ACT dated on 2015-01-26: Actavis Registration Statement for

Pending Acquisition of Allergan Declared Effective by the SEC

Financial news for ACT dated on 2015-01-26: Actavis Surges Amid Acquisition Of Auden Mckenzie For PS306 Million

Financial news for ACT dated on 2015-01-26: It's A 'Merger Monday'! From Corn Flakes To Drugs, Activity Is Heating Up

Financial news for ACT dated on 2015-01-26: UPDATE: Activist Expects Auden Mckenzie Acquisition To Close In Q1 2015

Financial news for ACT dated on 2015-01-26: UPDATE: Actavis Reports Purchase of Auden Mckenzie for PS306M

Financial news for ACT dated on 2015-01-26: Actavis Reports Purchase of Auden Mckenzie for PS306M

Financial news for ACT dated on 2015-01-20: Richter, Actavis Announce Positive Phase III Results for Cariprazine in Prevention of Relapse in Patients with Schizophrenia

Financial news for ACT dated on 2015-01-15: Actavis Seeks Allergan CEO Pyott as Board Member Once Allergan Takeover Deal Closes, According to Sources -Reuters

Financial news for ACT dated on 2015-01-14: After Hours Movers

Financial news for ACT dated on 2015-01-14: 8-K from Galena, Partner Orexo, Received Paragraph IV Patent Certification Notice from Actavis Related to Abstral Generic

Financial news for ACT dated on 2015-01-13: From JPMorgan Healthcare Conference: Actavis Sees FY2017 EPS \$25.00

Financial news for ACT dated on 2015-01-13: Actavis Reports Launch of US Generic Specialty Injectable Portfolio; Says Will Immediately Begin Marketing 20 Injectable Products

Financial news for ACT dated on 2015-01-12: Actavis Reports 'Exceptional' Prelim. Q4 Results: Expecting to Beat Q4 Adj. EPS Figure by 10-15%

Financial news for ACT dated on 2015-01-12: Actavis, Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period

Financial news for ACT dated on 2015-01-11: Adamas Pharmaceuticals Recaps 2014 Achievements, Previews Upcoming Business Drivers

Financial news for ACT dated on 2015-01-06: Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA IR

Financial news for ACT dated on 2015-01-06: US Stock Futures Edge Higher Ahead Of Economic Data

Financial news for ACT dated on 2015-01-06: Actavis, Gedeon Richter Announce FDA Receives NDA Resubmission for Cariprazine

Financial news for ACT dated on 2014-12-24: Adamas Pharmaceuticals Shares Rise 20% Premarket on FDA Approval of Alzheimer's Treatment

Financial news for ACT dated on 2014-12-24: Actavis, Adamas Report FDA Approval of Namzaric for Treatment of Moderate to Severe Alzheimer's

Financial news for ACT dated on 2014-12-22: Actavis Names Jonathon Kellerman EVP, Global Chief Compliance Officer

Financial news for ACT dated on 2014-12-22: Actavis 8-K Shows \$1B Revolving Credit Facility Replacing Existing \$750M Pact; Term Loan Credit Pact In 2 Tranches Of \$2.75B Each

Financial news for ACT dated on 2014-12-19: Actavis' XYDALBA Receives CHMP Positive Opinion

Financial news for ACT dated on 2014-12-19: Actavis Could Be Weighing Offer for Almirall

Financial news for ACT dated on 2014-12-19: EMA Has Recommended Actavis's Levofloxacin, Dalbavancin

Financial news for ACT dated on 2014-12-18: Ackman: Allergan Is A Good Merger Arbitrage Play, Potential 28% Upside

Financial news for ACT dated on 2014-12-17: Ackman Says 'Still Own Every Share of

Allergan,' Except for Piece Valeant Purchased

Financial news for ACT dated on 2014-12-16: Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition

Financial news for ACT dated on 2014-12-15: Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA(r) IR

Financial news for ACT dated on 2014-12-15: Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA

Financial news for ACT dated on 2014-12-11: Actavis Reports Confirmation of District Court Ruling to Require Continued Distribution of NAMENDA IR, Co. Says Will Immediately Appeal Decision

Financial news for ACT dated on 2014-12-10: Actavis Reports Launch of Generic Version of Pfizer's Celebrex

Financial news for ACT dated on 2014-12-09: Valeant Abandoning its Growth by Acquisition Strategy -Reuters

Financial news for ACT dated on 2014-12-05: Actavis Release Confirms FDA Panel Recommended Approval of Ceftazidime-Avibactam

Financial news for ACT dated on 2014-12-05: Actavis' Antibiotic Ceftazidime/avibactam Receives Partial FDA Panel Backing

Financial news for ACT dated on 2014-12-05: How To Profit From An Aging Population

Financial news for ACT dated on 2014-12-04: Morgan Stanley Maintains Overweight on Actavis, Raises PT to \$315.00

Financial news for ACT dated on 2014-12-01: UPDATE: Actavis Launches Generic Version of Intuniv

Financial news for ACT dated on 2014-12-01: Actavis Launches Generic Version of Intuniv

Financial news for ACT dated on 2014-11-26: Barclays Assumes Actavis at Equal-weight, Announces \$268.00 PT

Financial news for ACT dated on 2014-11-21: #PreMarket Primer: Friday, November 21: Immigration Reform Could Have Lasting Impact In More Ways Than One

Financial news for ACT dated on 2014-11-18: Dow, S&P 500 Add To Gains Following Encouraging International News

Financial news for ACT dated on 2014-11-18: FBR Analyst Discussed Valeant Following ACT-AGN Deal: Believes Likely Co. Will Do 'Sizeable Deal' Before Mid '15, Another Smaller Deal Later in Year

Financial news for ACT dated on 2014-11-18: Bill Ackman Says He Supports The Allergan-Actavis Deal And CEO Brent Saunders

Financial news for ACT dated on 2014-11-18: Ackman Pledges Support For Actavis Bid On Allergan

Financial news for ACT dated on 2014-11-18: Nikkei Reports Mizuho Bank Joining JPMorgan Chase, Wells Fargo in Financing Actavis' Purchase of Allergan; Banks to Provide \$45B Bridge Loan for \$66B Deal

Financial news for ACT dated on 2014-11-18: Ackman to Withdraw Special Meeting Over Allergan; Says he Supports Actavis Deal -CNBC

Financial news for ACT dated on 2014-11-18: Is Bill Ackman Back?

Financial news for ACT dated on 2014-11-18: Benzinga's Volume Movers

Financial news for ACT dated on 2014-11-18: Citi Raises Price Target On Actavis

Financial news for ACT dated on 2014-11-18: Citigroup Maintains Buy on Actavis, Raises PT to \$310.00

Financial news for ACT dated on 2014-11-18: #PreMarket Primer: Tuesday, November 18: Abe To Delay Sales Tax Increase In Japan

Financial news for ACT dated on 2014-11-17: Benzinga's M&A Chatter for Monday November 17, 2014

Financial news for ACT dated on 2014-11-17: 3 Stocks (And 4 Trades) Blowing Up On Twitter

Financial news for ACT dated on 2014-11-17: U.S. Markets Recover From Early-Day Losses As Japan's Economy Contracts

Financial news for ACT dated on 2014-11-17: Mid-Day Market Update: Allergan Jumps On Actavis Bid; Denbury Resources Shares Slip

Financial news for ACT dated on 2014-11-17: Top Performing Industries For November 17, 2014

Financial news for ACT dated on 2014-11-17: Mid-Morning Market Update: Markets Edge Lower; Halliburton To Acquire Baker Hughes For \$34.6 Billion

Financial news for ACT dated on 2014-11-17: Benzinga's Volume Movers

Financial news for ACT dated on 2014-11-17: Stocks Hitting 52-Week Highs

Financial news for ACT dated on 2014-11-17: Actavis plc Buying Allergan In \$66 Billion Deal

Financial news for ACT dated on 2014-11-17: Morning Market Movers

Financial news for ACT dated on 2014-11-17: Valeant Offers Comment on Allergan Deal: Says Can Not Justify Holders Paying \$219+ for Allergan

Financial news for ACT dated on 2014-11-17: Actavis to Acquire Allergan To Create Top 10 Global Growth Pharmaceutical Company with \$23B In Revenue

Financial news for ACT dated on 2014-11-17: UPDATE: David Faber Tweets: 'Actavis to buy Allergan for \$129 in cash and .3683 ACT share. Deal worth \$219 at open of trading.'

Financial news for ACT dated on 2014-11-17: CNBC Reports Actavis to Acquire Allergan for \$219/Share

Financial news for ACT dated on 2014-11-17: CNBC's David Faber Reporting Actavis to Buy Allergan for \$129/Share Plus 0.3683 ACT Share

Financial news for ACT dated on 2014-11-17: Allergan Spikes Higher

Financial news for ACT dated on 2014-11-17: #PreMarket Primer: Monday, November 17: Japan's Economy Unexpectedly Slips

Financial news for ACT dated on 2014-11-17: Must Watch Stocks for Today

Financial news for ACT dated on 2014-11-16: Benzinga's Weekend M&A Chatter

Financial news for ACT dated on 2014-11-16: Actavis, Allergan Could Announce Merger Deal Monday

Financial news for ACT dated on 2014-11-16: WSJ Reports Allergan, Actavis Close to Merger Deal, Could be Announced Monday, According to Source

Financial news for ACT dated on 2014-11-14: Report: Pfizer 'Unlikely' To Pursue Acquisition Of AstraZeneca

Financial news for ACT dated on 2014-11-13: Actavis Announces FDA Acceptance of sNDA for SAPHRIS (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients

Financial news for ACT dated on 2014-11-12: All Quiet On The Market Front: Dow, S&P 500, Nasdaq Virtually Flat

Financial news for ACT dated on 2014-11-12: Allergan Spikes Higher On Acquisition Report

Financial news for ACT dated on 2014-11-12: Actavis Rumored to Be in Talks to Buy Allergan for \$60B, ~\$200/Share

Financial news for ACT dated on 2014-11-10: Actavis Names Maria Teresa Hilado CFO

Financial news for ACT dated on 2014-11-06: Actavis Shares Tick Lower Ahead of Bloomberg Headline Suggesting Co. is Gauging Investor Response to Allergan Bid

Financial news for ACT dated on 2014-11-06: Reports: Allergan In Talks With Actavis

Financial news for ACT dated on 2014-11-06: Salix Pharma Shares Volatile, Slightly Lower as Bloomberg Reporting Co. Talks with Actavis Have Been Put on Hold

Financial news for ACT dated on 2014-11-05: 10-Q from Actavis Shows Co. Received Civil Investigative Demand from Attorney General of Texas on Oct. 22nd

Financial news for ACT dated on 2014-11-05: Dow, S&P 500 Close At Record Highs

Financial news for ACT dated on 2014-11-05: Actavis CFO R. Todd Joyce to Retire in Early 2015

Financial news for ACT dated on 2014-11-05: Actavis Reports Q3 EPS of \$3.19 vs \$3.10 Est; Revenue of \$3.68B vs \$3.62B Est

Financial news for ACT dated on 2014-11-03: Benzinga's M&A Chatter for Monday November 3, 2014

Financial news for ACT dated on 2014-11-03: Markets Mixed As Oil Continues To Drop

Financial news for ACT dated on 2014-11-03: WSJ Reporting Allergan's M&A Head David Lawrence Has Left Co.

Financial news for ACT dated on 2014-11-03: Report: Allergan Approached By Actavis

Financial news for ACT dated on 2014-11-03: WSJ's Liz Hoffman Tweets: 'Allergan confirms prior M&A approach from mystery co (source says Actavis). Sounds like door still open [\\$AGN](http://1.usa.gov/lwrPmTy)'

Financial news for ACT dated on 2014-11-03: WSJ Reporting Allergan Confirmed Prior M&A Approach from Actavis

Financial news for ACT dated on 2014-10-31: Actavis & Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata

Financial news for ACT dated on 2014-10-30: Benzinga's M&A Chatter for Thursday October 30, 2014

Financial news for ACT dated on 2014-10-23: Glenview Capital May Have Taken Stake in Actavis

Financial news for ACT dated on 2014-10-23: Actavis Confirms Appeals Court Upholds Lo Loestrin Fe Patent

Financial news for ACT dated on 2014-10-22: Actavis Reports Signing of Option to Buy Rhythm Unit, Relamorelin

Financial news for ACT dated on 2014-10-20: Report: Actavis, Sanofi To Bid On Over-The-Counter Drug Maker

Financial news for ACT dated on 2014-10-20: Benzinga's M&A Chatter for Monday October 20, 2014

Financial news for ACT dated on 2014-10-20: UPDATE: Omega Pharma Valued at EUR4B

Financial news for ACT dated on 2014-10-20: Actavis May Have Joined Bidding for Omega Pharma, Sanofi, Perrigo, Boehringer Also Considering Offer

Financial news for ACT dated on 2014-10-16: Will Actavis Win Competition For Allergan's Affection?

Financial news for ACT dated on 2014-10-16: Actavis Confirms Generic Quillivant XR(r) Patent Challenge

Financial news for ACT dated on 2014-10-10: UPDATE: Fidelity is Actavis' Largest Shareholder; Fidelity Increased Allergan Stake by ~2M Shares from End June-End August

Financial news for ACT dated on 2014-10-10: Reuters Reports Fidelity Supports Actavis-Allergan Merger

Financial news for ACT dated on 2014-10-09: Salix Pharma Spikes to High

Financial news for ACT dated on 2014-10-08: #PreMarket Primer: Wednesday, October 8: IMF Cuts Global Growth Prospects, Puts A Damper On Wall Street

Financial news for ACT dated on 2014-10-07: Benzinga's M&A Chatter for Tuesday October 7, 2014

Financial news for ACT dated on 2014-10-07: Dow Suffers Largest Daily Decline Since July, S&P 500 At 8-Week Lows On Global Growth Concerns

Financial news for ACT dated on 2014-10-07: Allergan, Inc. Spikes On Renewed Interest

From Actavis PLC

Financial news for ACT dated on 2014-10-07: UPDATE: Actavis Could Reiterate Takeover Interest in Allergan; Sources Say Allergan Would Consider Bid of \$200 or More -Reuters

Financial news for ACT dated on 2014-10-07: Reuters Reports Actavis Could Acquire Allergan for \$200/Share -Sources

Financial news for ACT dated on 2014-10-06: Benzinga's M&A Chatter for Monday October 6, 2014

Financial news for ACT dated on 2014-10-06: Markets Begin The Week On A Losing Note Ahead Of Earnings Kick-Off, Fed Minutes

Financial news for ACT dated on 2014-10-06: EZchip Falls On Lowered Sales Forecast; Durata Therapeutics Shares Jump

Financial news for ACT dated on 2014-10-06: U.S. Stocks Turn Red; CareFusion Shares Surge On Announcement Of Acquisition By Becton, Dickinson

Financial news for ACT dated on 2014-10-06: Markets Open Higher; Hewlett-Packard Plans To Split Into Two Companies

Financial news for ACT dated on 2014-10-06: Benzinga's Volume Movers

Financial news for ACT dated on 2014-10-06: Stocks Hitting 52-Week Highs

Financial news for ACT dated on 2014-10-06: Morning Market Movers

Financial news for ACT dated on 2014-10-06: Durata Therapeutics Shares to Resume Trading at 8:30 AM ET

Financial news for ACT dated on 2014-10-06: UPDATE: Actavis Announces Purchase of Durata Therapeutics for \$23/Share in Cash, CVR

Financial news for ACT dated on 2014-10-06: Actavis Announces Purchase of Durata Therapeutics for \$23/Share in Cash, CVR

Financial news for ACT dated on 2014-10-03: Salix Shares Rise 4.5% Premarket Following Announcement of Termination of Merger Agreement with Cosmo

Financial news for ACT dated on 2014-10-02: Salix Pharma Spikes Higher; In Talks to Sell to Actavis -Bloomberg

Financial news for ACT dated on 2014-09-25: Actavis Release Confirms Patent Challenge for Generic Butrans

Financial news for ACT dated on 2014-09-24: Benzinga's M&A Chatter for Wednesday September 24, 2014

Financial news for ACT dated on 2014-09-24: CNBC's David Faber Says Actavis and Salix in Early Stage Discussions Regarding Potential Deal

Financial news for ACT dated on 2014-09-23: Benzinga's M&A Chatter for Tuesday September 23, 2014

Financial news for ACT dated on 2014-09-23: UPDATE: Pfizer Has Weighed Other Options Including an Offer for AstraZeneca

Financial news for ACT dated on 2014-09-23: UPDATE: Pfizer Seeking Friendly Inversion Deal

Financial news for ACT dated on 2014-09-23: Pfizer Approached Actavis About Possible Deal

Financial news for ACT dated on 2014-09-23: Actavis Spikes Higher

Financial news for ACT dated on 2014-09-23: #PreMarket Primer: Tuesday, September 23: First Airstrikes In Syria Begin

Financial news for ACT dated on 2014-09-23: Stocks To Watch For September 23, 2014

Financial news for ACT dated on 2014-09-22: Benzinga's M&A Chatter for Monday September 22, 2014

Financial news for ACT dated on 2014-09-22: Dow Jones Reports Allergan Rejected Takeover Bid from Actavis in August; Actavis Still Interested in Allergan Deal; Allergan in Talks to Acquire Salix, According to Sources

Financial news for ACT dated on 2014-09-22: Barclays Downgrades Actavis to Equal-weight, Maintains \$250.00 PT

Financial news for ACT dated on 2014-09-15: Option Alert: Actavis Dec \$265 Call; 4,028 Contracts Traded vs 19 OI; Currently \$233.20

Financial news for ACT dated on 2014-09-14: Benzinga's Weekend M&A Chatter

Financial news for ACT dated on 2014-09-12: Shares of Actavis Spiking Higher; Note Being Passed Around Mentioning Potential Pfizer Acquisition of Actavis

Financial news for ACT dated on 2014-09-10: Sterne Agee Still Has Confidence In Actavis plc

Financial news for ACT dated on 2014-09-09: FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA For Treatment Of Hypertension

Financial news for ACT dated on 2014-09-09: Actavis CEO Saunders Currently Speaking on Morgan Stanley Webcast: Co. Remains Very Active in M&A, Sees Best Opportunity for Cash as Investing in Operations

Financial news for ACT dated on 2014-09-05: Actavis Announces FDA Acceptance of NDA Filing for Ceftazidime-Avibactam

Financial news for ACT dated on 2014-09-04: With Actively Managed Funds, Be Wary Of Expense Ratios

Financial news for ACT dated on 2014-09-04: Sterne Agee Raises Actavis plc Estimates, Price Target

Financial news for ACT dated on 2014-09-04: Shares Of Actavis Are Up ~1.5% On FDA Approval

Financial news for ACT dated on 2014-09-04: UPDATE: Morgan Stanley Reiterates On Actavis plc As M&A Could Offer Additional Upside

Financial news for ACT dated on 2014-09-04: Actavis's Watson Labs ANDA Approved By FDA

Financial news for ACT dated on 2014-09-02: Actavis Reports FDA Acceptance for Filing of NDA for Eluxadoline, Sees PDUFA Date in Q2 of 2015

Financial news for ACT dated on 2014-08-22: Actavis Announces Filing of Abbreviated NDA For Generic Neupro

Financial news for ACT dated on 2014-08-21: Pfizer Could Revive AstraZeneca Bid As Early As Tuesday

Financial news for ACT dated on 2014-08-21: Supernus Reports Paragraph IV ANDA Filing for Trokendi XR(R), Co. Says Actavis Filed ANDA for Topiramate Caps

Financial news for ACT dated on 2014-08-20: Pfizer Could Be Exploring Alternatives to Deal with AstraZeneca, May Consider Other Targets, Including Actavis - Bloomberg

Financial news for ACT dated on 2014-08-19: Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs

Financial news for ACT dated on 2014-08-19: Depomed Confirms Prevails in Gralise ANDA Litigation vs Actavis, Blocks Generic Entry Until 2024

Financial news for ACT dated on 2014-08-19: Depomed Prevails Against Actavis In Gralise Case

Financial news for ACT dated on 2014-08-19: Hearing Positive Court Ruling for Depomed vs Actavis

Financial news for ACT dated on 2014-08-19: Actavis Reports Results from Phase III Program of Ceftazidime-Avibactam Met Objective of Statnon-Inferiority

Financial news for ACT dated on 2014-08-14: 13F from Leon Cooperman's Omega Recently Filed: Showed New Stake in Apple, Liquidated Stakes in SunPower, Dollar General, Raised Stakes in Actavis, SUPERVALU, Reduced Stakes in Capital One, Qualcomm, Sprint

Financial news for ACT dated on 2014-08-06: Actavis Receives Neutral Rating from Zacks

Financial news for ACT dated on 2014-08-05: UPDATE: Actavis Posts Upbeat Q2 Earnings,

Raises Forecast

Financial news for ACT dated on 2014-08-05: Actavis Reports Q2 EPS of \$3.42 vs \$3.36 Est

Financial news for ACT dated on 2014-08-05: Earnings Scheduled For August 5, 2014

Financial news for ACT dated on 2014-08-01: 4.2M+ Share Block Trade in Actavis @\$216.00 at 2:36 PM ET

Financial news for ACT dated on 2014-07-29: Daniel Loeb's Hedge-Fund Returned \$1.4B to Investors In 2013; Told Investors Tuesday There are More Investment Opportunities -DJ

Financial news for ACT dated on 2014-07-29: UPDATE: Bank Of America Reiterates On Actavis plc On Strong Strategic/Financial Position

Financial news for ACT dated on 2014-07-25: Activis Shares Languish Post-Forest Deal

Financial news for ACT dated on 2014-07-21: Medicines360 And Actavis Announce FDA Acceptance For Filing Of NDA For Levosert(tm) IUD

Financial news for ACT dated on 2014-07-21: Markman Advisors Tweet: '\$DEPO Opinion in the case against \$ACT following a bench trial is expected shortly'

Financial news for ACT dated on 2014-07-16: Did Delivering Alpha Mavens Move Market?

Financial news for ACT dated on 2014-07-16: Actavis Looks To Keep Up Momentum In Spite Of Yellen's Report

Financial news for ACT dated on 2014-07-16: Leon Cooperman of Omega Advisors Likes Actavis

Financial news for ACT dated on 2014-07-11: Actavis Release Confirms Patent Challenge on Generic Diclegis, Says Filed ANDA

Financial news for ACT dated on 2014-07-08: Actavis Release Confirms Generic Ampyra Patent Challenge, Notes Filing of ANDA

Financial news for ACT dated on 2014-07-02: Markets Little Changed Ahead Of 4th Of July Break

Financial news for ACT dated on 2014-07-01: UPDATE: Filing from Icahn on Forest Labs Shows Liquidated Position; Had Previously Shown 11.25% Stake as of Mar. 31st

Financial news for ACT dated on 2014-07-01: Furiex Announces Approval of Purchase by Actavis by Shareholders

Financial news for ACT dated on 2014-07-01: Actavis Names Paul Bisaro as Exec. Chair

Financial news for ACT dated on 2014-06-30: Actavis, Forest Labs Confirm Received US FTC Clearance for Deal

Financial news for ACT dated on 2014-06-30: FTC Places Conditions on Actavis' Purchase of Forest Labs, Agree to Sell Rights to Four Generics

Financial news for ACT dated on 2014-06-30: Actavis Announces Abbreviated New Drug Application Filed With the FDA To Market Generic Zubsolv

Financial news for ACT dated on 2014-06-30: Actavis Files ANDA for Generic Zubsolv

Financial news for ACT dated on 2014-06-27: Canaccord Genuity Initiates Coverage on Actavis at Buy, Announces \$275.00 PT

Financial news for ACT dated on 2014-06-26: Among A Raft Of Index Changes, Affiliated Managers Group To Join S&P 500

Financial news for ACT dated on 2014-06-26: Acorda Therapeutics Announces Notification Of ANDA Filing For AMPYRA

Financial news for ACT dated on 2014-06-25: Shire Announces Vyvanse Patents Found to Be Infringed and Valid by US District Court

Financial news for ACT dated on 2014-06-24: Actavis and Forest Announce Tentative Election Deadline of June 27, 2014

Financial news for ACT dated on 2014-06-23: Bulls Take A Break As Dow's Winning Streak Ends At 7 Days

Financial news for ACT dated on 2014-06-23: Actavis, Forest Labs Announce C. David Nicholson as Head of Actavis Global Brands R&D

Financial news for ACT dated on 2014-06-23: JP Morgan Reinstates Overweight on Actavis, Announces \$300.00 PT

Financial news for ACT dated on 2014-06-19: Actavis Release Confirms District Court Ruling Related to Generic Exelon Patch Patent Suit, Court Said Claims Infringed

Financial news for ACT dated on 2014-06-18: Market Wrap For June 18: Markets Rally On Fed Comments And Tapering

Financial news for ACT dated on 2014-06-18: UPDATE: Morgan Stanley Resumes Coverage On Actavis Following Forest Acquisition

Financial news for ACT dated on 2014-06-18: Morgan Stanley Reinstates Overweight on Actavis, Announces \$246.00 PT

Financial news for ACT dated on 2014-06-17: Actavis Announces Forest Labs Acquisition Approved By Shareholders of Forrest

Financial news for ACT dated on 2014-06-12: VIVUS Reports Suit Against Actavis, Cites Infringement of Qsymia Patents

Financial news for ACT dated on 2014-06-11: Wells Fargo Initiates Coverage On The Pharmaceutical Space

Financial news for ACT dated on 2014-06-11: Wells Fargo Initiates Coverage on Actavis at Outperform

Financial news for ACT dated on 2014-06-10: Allergan Patents on Latisse Invalidated by US Appeals Court, Actavis, Sandoz Have Won Right to Sell Generic Eyelash Drug - Bloomberg

Financial news for ACT dated on 2014-05-30: Actavis Announces Nuvigil Patent Challenge Settlement

Financial news for ACT dated on 2014-05-27: Actavis Confirms Generic Onglyza Patent Challenge

Financial news for ACT dated on 2014-05-22: Market Wrap For May 22: Markets Barely Positive

Financial news for ACT dated on 2014-05-22: UPDATE: Sterne Agee Reiterates On Actavis PLC On Good Market Position

Financial news for ACT dated on 2014-05-22: Sterne Agee Maintains Buy on Actavis, Raises PT to \$250.00

Financial news for ACT dated on 2014-05-20: UPDATE: Actavis Shows Co. J&J's Janssen Have Amended Supply Deal for Generic Concerta

Financial news for ACT dated on 2014-05-20: Form 8-K from Actavis Shows Co. J&J's Janssen Have Amended Supply Deal for Generic Concerta

Financial news for ACT dated on 2014-05-15: 13F Filing from Stephen Mandel's Lone Pine Shows New Stakes in Actavis, Adobe, Jazz Pharma, Liquidated Positions in AmEx, Mead Johnson, Dollar Tree, Kinder Morgan

Financial news for ACT dated on 2014-05-15: Actavis, Apple Shares Unaffected as Several Sources Highlighting Bullish Comments from Omega's Leon Cooperman on CNBC

Financial news for ACT dated on 2014-05-15: Daniel B. Ravicher Tweet: 'Parties for @Celgene \$CELG v @Actavis \$ACT Revlimid patents Markman hearing in the courtroom, ready to start at 10'

Financial news for ACT dated on 2014-05-15: Actavis Extends Exclusive Distribution Agreement for Generic Concerta

Financial news for ACT dated on 2014-05-14: Actavis Announces Brent Saunders to be Named CEO and President

Financial news for ACT dated on 2014-05-13: Actavis Recives FDA Approval for Generic Exalgo

Financial news for ACT dated on 2014-05-12: Market Wrap For May 12: Dow And S&P Close At Record Highs

Financial news for ACT dated on 2014-05-12: RBC Capital Upgrades Actavis to Top Pick,

Raises PT to \$259.00

Financial news for ACT dated on 2014-05-12: Actavis Acanya Patent Settlement Gives Actavis License to market Acanya Starting in 2018

Financial news for ACT dated on 2014-05-12: Actavis Announces Settlement of Acanya Gel Patent Challenge, Strikes Deal with Valeant

Financial news for ACT dated on 2014-05-06: Top Acquisitions Of Big Tech Companies

Financial news for ACT dated on 2014-05-05: Actavis, Forest Labs Announce Effectiveness of Registration Statement

Financial news for ACT dated on 2014-05-01: Market Wrap For May 1: Markets Mixed To Start The New Month

Financial news for ACT dated on 2014-04-30: Market Wrap For April 30: Markets Positive Despite Fed Tapering and GDP Rising Less Than Expected

Financial news for ACT dated on 2014-04-29: Market Wrap For April 29: Dow Approaches Record Highs Despite Ongoing Ukraine Tension and Upcoming Fed Meeting

Financial news for ACT dated on 2014-04-28: Benzinga's M&A Chatter for Monday April 28, 2014

Financial news for ACT dated on 2014-04-28: UPDATE: Actavis Announces Suing FDA Related to Delay of Generic Celebrex Approval

Financial news for ACT dated on 2014-04-28: Actavis Announces Suing FDA Related to Delay of Generic Celebrex Approval

Financial news for ACT dated on 2014-04-28: Moody's Says Forest Lab's Purchase of Furiex is Credit Negative for Actavis

Financial news for ACT dated on 2014-04-24: Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns

Financial news for ACT dated on 2014-04-24: Actavis Announces Celebrex Patent Challenge Settlement

Financial news for ACT dated on 2014-04-17: Market Wrap For April 17: Mixed Earnings Drag The Dow Lower While S&P 500 & Nasdaq End Positive

Financial news for ACT dated on 2014-04-17: Actavis to Acquire Four Products from Akorn; Terms Undisclosed

Financial news for ACT dated on 2014-04-17: National Alliance Initiates Coverage on Actavis at Buy, Announces \$246.00 PT

Financial news for ACT dated on 2014-04-16: Market Wrap For April 16: Markets Hold On To Gains On Positive Yellen Comments And Economic Data

Financial news for ACT dated on 2014-04-16: Sterne Agee Sees 16% Upside for Actavis, Initiates Coverage

Financial news for ACT dated on 2014-04-16: Benzinga's Top Initiations

Financial news for ACT dated on 2014-04-16: Sterne Agee Initiates Coverage on Actavis at Buy, Announces \$230.00 PT

Financial news for ACT dated on 2014-04-15: Actavis Reports Deal Related to Generess FE Patent Challenge, Will Grant Mylan License to MTK Generic Version

Financial news for ACT dated on 2014-04-09: Market Wrap For April 9: Investors Breathe Sigh Of Relief Over Rate Worries

Financial news for ACT dated on 2014-04-09: Susquehanna Upgrades Actavis to Positive, Raises PT to \$260.00

Financial news for ACT dated on 2014-04-01: Actavis Reports Purchase of Silom Medical Co. for ~\$100M in Cash, Will Immediately Add to Adj. Earnings in 2014

Financial news for ACT dated on 2014-04-01: Actavis Completes Divestiture of Commercial Operations in Seven Western European Countries to Aurobindo Pharma Limited

Financial news for ACT dated on 2014-03-28: US Federal Circuit Court Of Appeals Reverses Lower Court Finding That Competing Product from Actavis' Watson Unit Infringed Shire Patent

Financial news for ACT dated on 2014-03-28: Shire Has Lost Appeal Ruling in Actavis Case Related to Lialda

Financial news for ACT dated on 2014-03-25: UPDATE: Actavis and Valeant Announce FDA Approval for Metronidazole 1.3%

Financial news for ACT dated on 2014-03-25: Actavis, Valeant Report FDA Approval for Metronidazole 1.3%

Financial news for ACT dated on 2014-03-19: UPDATE: Actavis Says Noven Will Grant Royalty-Bearing License

Financial news for ACT dated on 2014-03-19: Actavis Announces Daytrana Patent Challenge Settlement

Financial news for ACT dated on 2014-03-13: Market Wrap For March 13: Bears Come Out Of Hibernation As Dow Suffers Largest Daily Loss Since February 3

Financial news for ACT dated on 2014-03-12: Actavis Confirms Favorable Ruling in Generic Celebrex Patent Suit

Financial news for ACT dated on 2014-03-07: US Stock Futures Edge Higher; All Eyes On Jobs Report

Financial news for ACT dated on 2014-03-07: UPDATE: Columbia Laboratories Buys Back 1.4M Shares of Common Stock from Actavis at \$6.08/Share

Financial news for ACT dated on 2014-03-07: Columbia Laboratories Buys Back 1.4M Shares Of Common Stock From Actavis

Financial news for ACT dated on 2014-02-28: Actavis Confirms Generic Colcrys Patent Challenge

Financial news for ACT dated on 2014-02-28: Actavis Confirms Generic Multaq Patent Challenge

Financial news for ACT dated on 2014-02-25: Dow Jones Reports AstraZeneca Proposed \$70.00/Share Bid for Forest Laboratories, According to Sources

Financial news for ACT dated on 2014-02-21: #PreMarket Primer: Friday, February 21: Another Truce Reached In Ukraine

Financial news for ACT dated on 2014-02-20: Market Wrap For February 20: S&P 500 Inches Closer To New Highs

Financial news for ACT dated on 2014-02-20: Pharma ETFs On The Move Again (IHE, PJP, PPH, ACT, FRX)

Financial news for ACT dated on 2014-02-20: UPDATE: Actavis Posts Upbeat Q4 Earnings

Financial news for ACT dated on 2014-02-20: Actavis Reports Q4 Adj. EPS \$3.17

Financial news for ACT dated on 2014-02-20: Actavis Reports Q4 EPS of \$(0.86) Which May Not Compare \$3.05 Est; Revenue of \$2.78B Which May Not Compare \$2.68B Est

Financial news for ACT dated on 2014-02-20: Earnings Scheduled For February 20, 2014

Financial news for ACT dated on 2014-02-19: Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends Winning Streak

Financial news for ACT dated on 2014-02-19: S&P Downgrades Actavis from BBB to BBB-; Outlook Revised to Stable

Financial news for ACT dated on 2014-02-19: A High Expected Return Watch List

Financial news for ACT dated on 2014-02-19: UPDATE: Bank of America Reiterates on Actavis on Possible Forest Acquisition

Financial news for ACT dated on 2014-02-19: Benzinga's Top Upgrades

Financial news for ACT dated on 2014-02-19: Goldman Sachs Upgrades Actavis to Buy, Raises PT to \$250.00

Financial news for ACT dated on 2014-02-19: #PreMarket Primer: Wednesday, February 19: Tesla Earnings Expected Today

Financial news for ACT dated on 2014-02-19: Bank of America Maintains Buy on Actavis, Raises PO to \$235.00

Financial news for ACT dated on 2014-02-18: Benzinga's M&A Chatter for Tuesday February 18, 2014

Financial news for ACT dated on 2014-02-18: Actavis Announces Cancellation of Q4, FY13 Earnings Call on Feb. 20th, Will Provide Revised Earnings for Combined Co., Reaffirms Standalone FY14 Outlook

Financial news for ACT dated on 2014-02-18: Market Wrap For February 18: Dow Finishes Lower, Nasdaq Still Hot

Financial news for ACT dated on 2014-02-18: Mid-Afternoon Market Update: Actavis Acquisition of Forest Labs Dominates Headlines as Markets Remain Mixed

Financial news for ACT dated on 2014-02-18: Moody's Reviews Forest Labs For Upgrade

Financial news for ACT dated on 2014-02-18: Fitch Affirms Actavis at 'BBB-' on Forest Labs Acquisition; Outlook Stable

Financial news for ACT dated on 2014-02-18: Horizon Pharma IR Says Nothing Reported by Company Causing the Strength in Share Price; May be Attributed to Actavis Acquisition of Forest Labs

Financial news for ACT dated on 2014-02-18: Mid-Day Market Update: US Stocks Mostly Higher; Forest Laboratories Shares Jump On Actavis Deal

Financial news for ACT dated on 2014-02-18: Mid-Morning Market Update: Markets Mixed; Coca-Cola Posts Decline In Profit

Financial news for ACT dated on 2014-02-18: Benzinga's Volume Movers

Financial news for ACT dated on 2014-02-18: Top Trending Tickers On StockTwits For February 18

Financial news for ACT dated on 2014-02-18: Stocks Hitting 52-Week Highs

Financial news for ACT dated on 2014-02-18: From M&A Call: Actavis Exec Says Co. Will Not Pull Back from Generics R&D, Sees Spending About \$400M on R&D Moving Forward

Financial news for ACT dated on 2014-02-18: UPDATE: Forest Labs Shares Rise 31% on Acquisition by Actavis; Actavis Shares 8% Higher

Financial news for ACT dated on 2014-02-18: Actavis to Acquire Forest Labs for ~\$25B in Equity, Cash; Both Stocks Surge Higher

Financial news for ACT dated on 2014-02-18: Benzinga's Top #PreMarket Gainers

Financial news for ACT dated on 2014-02-18: #PreMarket Primer: Tuesday, February 18: Big Merger Deals In The Works

Financial news for ACT dated on 2014-02-18: US Stock Futures Flat Ahead Of Coca-Cola Earnings, Housing Data

Financial news for ACT dated on 2014-02-18: UPDATE: Actavis to Acquire Forest Laboratories for \$89.48/Share in Cash, Stock Deal

Financial news for ACT dated on 2014-02-18: Actavis to Acquire Forest Laboratories for \$25 Billion in an Equity and Cash Transaction

Financial news for ACT dated on 2014-02-17: Benzinga's Weekend M&A Chatter

Financial news for ACT dated on 2014-02-17: Dow Jones Reports Actavis to Acquire Forest Labs for as Much as \$25B, According to Sources

Financial news for ACT dated on 2014-02-04: #PreMarket Primer for Tuesday, February 4: Will The Plunge Continue?

Financial news for ACT dated on 2014-02-03: UPDATE: Morgan Stanley Increases PT on Actavis Due to Enhanced Visibility and Interest in M&A

Financial news for ACT dated on 2014-02-03: Morgan Stanley Maintains Overweight on Actavis, Raises PT to \$205.00

Financial news for ACT dated on 2014-01-31: Actavis Sees FY2014 EPS \$12.60-13.10 vs \$12.89 Est; Sees Sales \$10.0B+ vs \$10.47B Est

Financial news for ACT dated on 2014-01-31: Actavis Announces Refocused Global Business Structure

Financial news for ACT dated on 2014-01-24: Actavis Announces Deal with Zhejiang

Chiral Medicine Chemicals Co., to Divest Actavis Foshan, China

Financial news for ACT dated on 2014-01-22: Actavis Confirmed Submission of Application for Restasis Generic, ANDA Submitted to Prior to Issuance of FDA Guidance

Financial news for ACT dated on 2014-01-18: Actavis Announces Agreement with Aurobindo Pharma to Divest Commercial Operations in Seven Western European Countries

Financial news for ACT dated on 2014-01-17: Bloomberg Reporting Actavis Has Won Order Blocking Generic LO Loestrin FE Until 2029

Financial news for ACT dated on 2014-01-15: Actavis CEO at Conference Says Co. Quitting China, Calls Business Climate Difficult

Financial news for ACT dated on 2014-01-15: Actavis CEO Says Aiming for Double Digit Growth

Financial news for ACT dated on 2014-01-15: Actavis Sec Says Co. Expecting 2014 Sales of \$10B+ vs Analyst Estimate \$10.47B

Financial news for ACT dated on 2014-01-15: Actavis Exec Currently Speaking at JP Morgan's Healthcare Conf., Says Expecting Growth in Generics

Financial news for ACT dated on 2014-01-14: UPDATE: Allergan Has Won a Ruling Blocking Generics of Lumigan Until 2027

Financial news for ACT dated on 2014-01-14: Actavis Sees Q4 Adj. EPS Modestly Above High End of Previously-Issued Range

Financial news for ACT dated on 2014-01-10: UPDATE: Cowen Upgrades Actavis

Financial news for ACT dated on 2014-01-10: Benzinga's Top Upgrades

Financial news for ACT dated on 2014-01-10: Cowen & Company Upgrades Actavis to Outperform, Raises PT to \$215.00

Financial news for ACT dated on 2014-01-08: Actavis Wins FDA Approval for Generic Version of Micardis

Financial news for ACT dated on 2014-01-06: RBC Capital Initiates Coverage on Actavis at Outperform, Announces \$202.00 PT

Financial news for ACT dated on 2013-12-26: Merck Sues to Stop Generic NuvaRing

Financial news for ACT dated on 2013-12-24: Actavis Confirms Generic NuvaRing Patent Challenge

Financial news for ACT dated on 2013-12-24: Actavis Receives CRL from FDA for Patch

Financial news for ACT dated on 2013-12-16: Zimmer Holdings Names Paul Bisaro to Board of Directors

Financial news for ACT dated on 2013-12-11: Actavis Reports Tentative Deal Related to Asacol HD Patent Challenge with Zydus Pharma, Cadila

Financial news for ACT dated on 2013-11-26: Merrimack, Actavis Announce Nanotechnology Collaboration

Financial news for ACT dated on 2013-11-14: Actavis Confirms Patent Challenge of Generic Axiron, Says Lilly Filed Suit

Financial news for ACT dated on 2013-11-14: Columbia Laboratories to Receive One-time Payment of \$300K from Actavis for CRINONE US Manufacturing Rights

Financial news for ACT dated on 2013-11-08: DJ Reporting FDA Has Proposed Letting Generic Drugmakers Change Labels

Financial news for ACT dated on 2013-10-31: Actavis Confirms Generic Absorica Patent Challenge

Financial news for ACT dated on 2013-10-30: UPDATE: Barclays Capital Reiterates on Actavis PLC Following Share Price Movement

Financial news for ACT dated on 2013-10-30: UPDATE: Jefferies Reiterates on Actavis PLC Following In-Line Q3 Results, Solid '14 Guidance

Financial news for ACT dated on 2013-10-30: Jefferies Maintains hold on Actavis, Raises PT to \$168.00

Financial news for ACT dated on 2013-10-29: Actavis Sees FY2014 EPS \$12.25-13.00 vs \$11.38 Est

Financial news for ACT dated on 2013-10-29: Actavis Sees Q4 EPS \$2.95-3.05 vs \$2.26 Est

Financial news for ACT dated on 2013-10-29: Actavis Reports Q3 EPS of \$2.09, Inline; Revenue of \$2.01B vs \$2.04B Est

Financial news for ACT dated on 2013-10-25: UPDATE: Citigroup Initiates Coverage on Actavis PLC as Stock is Firing on All Cylinders

Financial news for ACT dated on 2013-10-25: Citigroup Initiates Coverage on Actavis at Buy, Announces \$172.00 PT

Financial news for ACT dated on 2013-10-23: Columbia Laboratories Announces Amended Class Action Lawsuit Dismissed without Prejudice

Financial news for ACT dated on 2013-10-08: Actavis Confirms Generic Xuboxone Sublingual Film Patent Challenge

Financial news for ACT dated on 2013-10-07: S&P Sets BBB CCR on Actavis; Outlook Negative

Financial news for ACT dated on 2013-10-02: Pharmaceutical Industry Expected To Collect Billions From Obamacare

Financial news for ACT dated on 2013-09-30: Irish Regulators Give Clearance for Actavis, Warner Chilcott Deal

Financial news for ACT dated on 2013-09-30: Amneal Pharmaceuticals to Acquire Four Generic Products from Actavis

Financial news for ACT dated on 2013-09-27: Actavis, Warner Chilcott Receive FTC Clearance for Actavis' Proposed Acquisition of Warner Chilcott

Financial news for ACT dated on 2013-09-27: Actavis Looking for FTC Approval to Sell Drug Rights to Amneal, Settles Over Warner Chilcott Deal

Financial news for ACT dated on 2013-09-27: Bloomberg Reporting Actavis Has Agreed to Sell Four Generics Under FTC Settlement;

Financial news for ACT dated on 2013-09-27: Bloomberg Reporting Actavis Seeking FTC Approval to Sell Drug Rights to Amneal

Financial news for ACT dated on 2013-09-16: Actavis Launches Generic Lidoderm with Endo, Teikoku

Financial news for ACT dated on 2013-09-12: Actavis Launches Generic Version of Opana ER

Financial news for ACT dated on 2013-09-10: Actavis, Warner Chilcott Holders Approve Proposals, Still Need Irish High Court Approval

Financial news for ACT dated on 2013-09-03: Avanir Pharma Reports Settlement of Nuedexta Patent Litigation with Actavis

Financial news for ACT dated on 2013-08-27: UPDATE: Actavis Confirms Generic Rayos Patent Challenge

Financial news for ACT dated on 2013-08-27: Actavis Confirms Patent Challenge for Generic Rayos

Financial news for ACT dated on 2013-08-16: Actavis Reports James D'Arecca Chief Accounting Officer

Financial news for ACT dated on 2013-08-14: Eton Park 13F Filing Shows New Stakes In Actavis, Baidu, CBS, Clearwire, Constellation Brands, Elan, Noble

Financial news for ACT dated on 2013-08-09: Actavis Wins Approval for Pending Warner Chilcott Purchase in France

Financial news for ACT dated on 2013-08-09: Actavis Receives Approval from French Competition Authority for Pending Warner Chilcott Acquisition

Financial news for ACT dated on 2013-08-06: Actavis Acquires Worldwide Rights for Palau Pharma's Albaconazole Antifungal Agent

Financial news for ACT dated on 2013-07-29: Leerink Swann Upgrades Actavis to

Outperform, Announces \$155.00 PT

Financial news for ACT dated on 2013-07-29: Actavis Confirms Generic Nucynta(r) ER Patent Challenge

Financial news for ACT dated on 2013-07-26: Forest Labs Shares Close at Session Highs as Leerink Swann Sees 'Imminent' Settlement with Actavis Related to Bystolic

Financial news for ACT dated on 2013-07-25: Actavis Narrows FY2013 EPS Guidance to \$8.15-8.50 vs \$8.32 Est

Financial news for ACT dated on 2013-07-25: Actavis Reports Q2 EPS of \$2.01 vs \$2.00 Est; Revenue of \$1.99B vs \$1.98B Est

Financial news for ACT dated on 2013-07-15: Actavis' Generic Version of Lamictal ODT Receives FDA Approval

Financial news for ACT dated on 2013-07-12: Actavis' Generic Opana ER Receives FDA Approval

Financial news for ACT dated on 2013-07-12: Actavis Confirms Generic Vimpat Patent Challenge

Financial news for ACT dated on 2013-07-11: Actavis, Warner Chilcott Receives FTC Second Request Under HSR

Financial news for ACT dated on 2013-07-11: Actavis and Warner Chilcott Receive FTC Second Request Under Hart-Scott-Rodino

Financial news for ACT dated on 2013-06-28: SLIDESHOW: Top 10 Performing S&P 500 Stocks of the Second Quarter

Financial news for ACT dated on 2013-06-24: Actavis Launches Generic Viagra in Europe

Financial news for ACT dated on 2013-06-18: Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition

Financial news for ACT dated on 2013-06-18: How the Supreme Court Caused Anger With 'Pay to Delay' (ACT)

Financial news for ACT dated on 2013-06-17: Actavis Announces Supreme Court Reverse Appeals Ruling in FTC v. Actavis

Financial news for ACT dated on 2013-06-14: Leerink Swann's Gerberry Sees a Likely Win or Settle from Actavis in Litigation with Novartis, Maintains Market Perform

Financial news for ACT dated on 2013-06-12: Actavis, Medicines360 Announce Partnership

Financial news for ACT dated on 2013-06-11: Actavis, Medicines360 Announce Partnership for Women's Access to Affordable IUDs, to Pay \$50M for Rights, to Pay Up to \$125M in Added Payments

Financial news for ACT dated on 2013-06-07: Actavis Confirms Generic Diprivan Patent Challenge, Filed ANDA for Generic of Fresenius Product

Financial news for ACT dated on 2013-06-02: CVR Energy, Warner Chilcott and Other Top Performers in May

Financial news for ACT dated on 2013-05-21: UPDATE: Piper Jaffray Raises PT on Actavis on Pro Forma Estimates

Financial news for ACT dated on 2013-05-21: Bernstein Believes Mylan Could Offer \$22/Share for Warner Chilcott, Calls Deal with Actavis More Likely

Financial news for ACT dated on 2013-05-21: UPDATE: Jefferies Reiterates Hold Rating, Raises PT on Actavis on WCRX Acquisition Announcement

Financial news for ACT dated on 2013-05-20: Benzinga's M&A Chatter for Monday May 20, 2013

Financial news for ACT dated on 2013-05-20: Morgan Stanley Lifts Price Target on Actavis from \$101 to \$140

Financial news for ACT dated on 2013-05-20: S&P Says Warner Chilcott May Be Raised

Financial news for ACT dated on 2013-05-20: JP Morgan Maintains Overweight on Actavis, Raises PT to \$150.00

Financial news for ACT dated on 2013-05-20: Pharma M&A - Actavis to Acquire Warner Chilcott

Financial news for ACT dated on 2013-05-20: Benzinga's Volume Movers

Financial news for ACT dated on 2013-05-20: Benzinga's Top Pre-Market Gainers

Financial news for ACT dated on 2013-05-20: UPDATE: Actavis to Acquire Warner Chilcott in \$8.5B Transaction; Price is \$20.08 per Share

Financial news for ACT dated on 2013-05-20: Actavis Shares Rise 4% Pre-Market on Warner Chilcott Acquisition

Financial news for ACT dated on 2013-05-20: PREVIEW: Warner Chilcott to Resume Trading at 7:30AM ET

Financial news for ACT dated on 2013-05-20: Actavis to Acquire Warner Chilcott for \$8.5B in Stock Deal

Financial news for ACT dated on 2013-05-17: Hearing Rumor of Warner Chilcott, Actavis Cancellation from UBS Conference

Financial news for ACT dated on 2013-05-16: Benzinga's Top Pre-Market Gainers

Financial news for ACT dated on 2013-05-16: Bloomberg Reporting Novartis Spokesperson Says Has 'No Intention' of Pursuing Actavis Bid

Financial news for ACT dated on 2013-05-16: Jefferies Maintains Hold on Actavis, Raises PT to \$120.00

Financial news for ACT dated on 2013-05-15: Hearing Novartis Considering Offer for Actavis

Financial news for ACT dated on 2013-05-15: UPDATE: Omega Advisors Open New Positions in Occidental, SUPERVALU, Covidien, Liquidated Western Union, Verifone, Humana, Actavis, WellPoint, Lowered Stakes in Google, DISH Networks, Raised Stake in Citi, QUALCOMM, Sprint

Financial news for ACT dated on 2013-05-15: Canaccord Analyst Saying New Mylan Deal Likely After Warner Chilcott, Actavis Reports

Financial news for ACT dated on 2013-05-14: Benzinga's M&A Chatter for Tuesday May 14, 2013

Financial news for ACT dated on 2013-05-14: Mylan Spikes Higher

Financial news for ACT dated on 2013-05-14: Actavis Says they have Only Confirmed Talks with Warner Chilcott, 'This is the Extent of What We have Confirmed or Discussed Publicly'

Financial news for ACT dated on 2013-05-14: Mylan Refers to Report of Bid for Actavis as Speculation, Declines Comment

Financial news for ACT dated on 2013-05-14: Bloomberg Reporting Actavis Said to Have Spurned \$15B from Mylan

Financial news for ACT dated on 2013-05-14: Actavis Makes Announcement Under Irish Takeover Rules

Financial news for ACT dated on 2013-05-13: Buckingham's Buck Says Warner Chilcott Deal Could Be Done at \$30/Share

Financial news for ACT dated on 2013-05-11: Benzinga's M&A Chatter for Friday May 10, 2013

Financial news for ACT dated on 2013-05-10: Market Wrap for Friday, May 10: Stocks Gain on Late Day Rally

Financial news for ACT dated on 2013-05-10: Warner Chilcott/Actavis Resumes Trading

Financial news for ACT dated on 2013-05-10: PREVIEW: Warner Chilcott to Resume at 3:05 PM ET

Financial news for ACT dated on 2013-05-10: Actavis Confirms It Is In Early Merger Talks with Warner Chilcott

Financial news for ACT dated on 2013-05-10: Actavis Halted Pending News

Financial news for ACT dated on 2013-05-10: Actavis Spikes Higher on Warner Chilcott

Bid Chatter

Financial news for ACT dated on 2013-05-10: Acatvis Spikes Lower on Warner Chilcott Takeover Report

Financial news for ACT dated on 2013-05-10: Bloomberg Reporting Actavis Said to Be in Early-Stage Talks to Buy Warner Chilcott

Financial news for ACT dated on 2013-05-10: BMO Capital Initiates Coverage on Actavis at Outperform, Announces \$124.00 PT

Financial news for ACT dated on 2013-05-09: Actavis Confirms District Court Ruling In Generic Lialda Patent Suit, Court Rules Actavis Infringed on Shire's Patent

Financial news for ACT dated on 2013-05-01: Allergen Combigan Patent to Expire in 2023 is Invalid, Gets Mixed Rulings in Combigan Appeal -Bloomberg

Financial news for ACT dated on 2013-05-01: Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel

Financial news for ACT dated on 2013-04-29: Benzinga's M&A Chatter for Monday April 29, 2013

Financial news for ACT dated on 2013-04-29: Actavis Spokesperson Declines Comment of Report of Takeover Talks with Valeant

Financial news for ACT dated on 2013-04-29: Valeant Pharmaceuticals Spokesperson Declines Comment on Speculation of Talks with Actavis

Financial news for ACT dated on 2013-04-28: Benzinga's M&A Chatter for Friday April 26, 2013

Financial news for ACT dated on 2013-04-27: Valeant in Talks to Acquire Actavis for \$13B -WSJ

Financial news for ACT dated on 2013-04-22: Intel Expands Its Pharmaceutical R&D

Financial news for ACT dated on 2013-04-17: Intel Expands Its Pharmaceutical R&D

Financial news for ACT dated on 2013-04-16: Actavis Confirms Favorable Ruling in Generic Yaz Patent Suit

Financial news for ACT dated on 2013-04-10: Actavis, Valeant Announce Deal to Launch Generic Versions of Ziana, Zyclara

Financial news for ACT dated on 2013-04-09: Columbia Laboratories Amends License Agreement with Merck Serono for CRINONE Ex-US to 2020

Financial news for ACT dated on 2013-04-05: Valeant to Supply Actavis with Generic Zovirax

Financial news for ACT dated on 2013-04-03: Actavis Confirms Court Issues TRO Preventing Distribution of Generic Pulmicort RESPULES

Financial news for ACT dated on 2013-04-01: Actavis Confirms Favorable Court Ruling in Patent Suit Involving Generic Version of AstraZeneca's Pulmicort RESPULES

Financial news for ACT dated on 2013-04-01: Actavis Files ANDA to Market Generic Version of AbbVie's Androgel

Financial news for ACT dated on 2013-03-25: Acxtavis Spikes to Highs

Financial news for ACT dated on 2013-03-25: Actavis Reaches Settlement with AstraZeneca; Will Launch Generic Version of Crestor in 2016

Financial news for ACT dated on 2013-03-21: JP Morgan Maintains Overweight on Actavis, Raises PT to \$102.00

Financial news for ACT dated on 2013-03-19: UPDATE: Goldman Sachs Raises PT on Actavis; Optionality with Generic Launches

Financial news for ACT dated on 2013-03-19: Goldman Sachs Maintains Neutral on Actavis, Raises PT to \$95.00

Financial news for ACT dated on 2013-03-18: Actavis Shares Underperform as Wells Fargo Downgraded to Market Perform

Financial news for ACT dated on 2013-03-01: Actavis Confirms Generic Fortesta Patent Challenge

Financial news for ACT dated on 2013-02-19: Actavis Sees FY2013 EPS \$7.70-8.10 vs \$8.00 Est

Financial news for ACT dated on 2013-02-19: Actavis Reports Q4 EPS of \$1.59 vs \$1.53 Est; Revenue of \$1.75B vs \$1.74B Est

Financial news for ACT dated on 2013-02-11: PetSmart and Other Secular Growth Picks (ACT, MYGN, PETM, HLF)